Peripheral blood lymphocytes from adult and adolescent chimpanzees, as well as adult humans, were studied for phenotypic surface markers by flow cytometry. Lymphocytes from chimpanzees were found to have increased numbers of Leu-1-, Leu-2+ cells as compared to humans. These cells, following preparative electronic cell sorting, were shown to possess natural killer function. Further analysis of this subpopulation indicated that they lacked responsiveness to a number of T-cell mitogens. The differences in lymphocyte subpopulations between chimpanzees and humans can almost be totally accounted for by the Leu-1-, Leu-2+ cells. Phylogenetic disparity between these two species may also be found within this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0008-8749(86)90386-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic value of immunosuppression scores in patients with esophageal squamous cell carcinoma: a multicenter study.
Front Immunol
January 2025
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Introduction: The prognostic impact of human leukocyte antigen-E (HLA-E) expression and the proportion of natural killer (NK) cells in esophageal squamous cell carcinoma (ESCC) was investigated.
Methods: This study retrospectively evaluated 397 ESCC patients across two centers. The cumulative incidence of recurrence (CIR) and the incidence of tumor-related death (CID) were analyzed in various groups.
Downregulation of MerTK in circulating T cells of patients with non-proliferative diabetic retinopathy.
Front Endocrinol (Lausanne)
January 2025
Department of Ophthalmology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Objective: To explore the differential gene expression in peripheral blood immune cells of individuals with type 2 diabetes mellitus (DM), comparing those with and without non-proliferative diabetic retinopathy (NPDR).
Methods: From a pool of 126 potential participants, 60 were selected for detailed analysis. This group included 12 healthy donors (HDs), 22 individuals with DM, and 26 with NPDR.
H2-K1 protects murine MLL-AF9 leukemia stem cells from natural killer cell-mediated immune surveillance.
Haematologica
January 2025
Division of Clinical Genetics, Lund Stem Cell Center, Lund University, 22184 Lund.
Not available.
View Article and Find Full Text PDFApplication of adoptive cell therapy in malignant melanoma.
J Transl Med
January 2025
Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employing immune cells with specific tumor-recognizing receptors, has emerged as a promising therapeutic approach to display on-tumor toxicity.
View Article and Find Full Text PDFThe molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells.
Pharmacol Res
January 2025
Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021, Shandong, China; Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China; Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. Electronic address:
Chimeric antigen receptor (CAR) T cells have encouraging results in the treatment of hematological malignancies. However, CAR-T therapy still faces numerous challenges against solid tumors, such as hepatocellular carcinoma (HCC), owing to heterogeneous antigen expression in tumor cells, limited persistence of CAR-T cells, etc. Therefore, to treat HCC more effectively, we connected the molecular receptor NKBB to a second-generation glypican-3 (GPC3) CAR to construct GC3328z-NKBB CAR-T cells, which have double specific targets of GPC3 and NKG2DLs (natural killer group 2, member D ligands), dual co-stimulation of CD28 and 41BB, and a single CD3ζ chain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!